Plasma Protein Products Growth, Trends & Forecast Outlook 2033

Plasma Protein Products by Type (/> Albumin, Immunoglobulin, Coagulation Factor, Others), by Application (/> Hospital, Retail Pharmacy, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $31500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $31500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Plasma Protein Products Market Size | CAGR 6.2 Forecast 2033

Plasma Protein Products Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $31500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $31500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Plasma Protein Products Market Overview

Plasma protein products (PPPs)—life-saving therapeutics derived from fractionated human plasma—span immunoglobulins, albumin, coagulation factors, and protease inhibitors. Their irreplaceable role in rare-disease management and critical care makes the Plasma Protein Products market size a bellwether for global biologics accessibility. With the 2025 baseline valuation at USD 34.2 billion, the sector is on track to reach USD 51.6 billion by 2033, reflecting a 5.9% CAGR and a robust growth outlook underpinned by aging demographics, rising PID and CID indications, and expanding albumin use in China’s public hospitals.

Loading chart…

North America commands >42% of global demand, yet Asia-Pacific is the fastest-expanding region, forecast to outpace 7% CAGR on expanded reimbursement and new fractionation plants in China and India. Key forces shaping the market forecast include: (1) Technology shifts to high-yield, closed-system chromatography that boosts IgG throughput 15–20%; (2) Regulatory tightening—EMA’s upcoming plasma-surveillance rules and China’s NMPA traceability mandate—raising compliance costs but also creating moats for top-tier players; and (3) Supply-chain dynamics, where recurrent plasma shortages and collection-center consolidation intensify competitive jockeying among Takeda, CSL, Grifols, and emergent Asian bios. Strategic planners should watch margin compression in albumin as volume-based procurement spreads beyond China, while immunoglobulin price premiums remain resilient, ensuring balanced industry expansion across the 2026–2033 horizon.

Report Overview

Report Attribute	Details
Market size value in 2025	31.50 billion
Revenue forecast in 2033	50.97 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; CBPO; Hualan Bio; Tiantan Bio; Shuanglin Bio; Boya Bio; Yuanda Shuyang; Weiguang Bio; Nanyue Bio; KM Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising prevalence of primary immunodeficiencies and neurological disorders is expanding the addressable patient base for IVIG and SCIG therapies, pushing the Plasma Protein Products market size beyond USD 30 B by 2028 and underpinning a 6-7 % CAGR growth forecast.

Next-generation plasmapheresis automation and real-time viral screening are lifting collection yields per litre by 12-15 %, enabling fractionators to scale output without proportional capex and protecting EBITDA margins amid tightening plasma supply.

Restraints

Regulators in the U.S. and EU are enforcing str-than-ever pathogen reduction validation and batch-release testing, adding USD 25-30 per litre to conversion costs and elongating lead times by 6-8 weeks, which compresses gross margins for mid-tier fractionators.

Prolonged albumin price deflation in China—driven by provincial volume-based procurement—has reset ASPs to 2014 levels, slicing >5 % off global revenue even as unit shipments rise, and forcing multinationals to reallocate quota to higher-margin coagulation factors.

Opportunities

Biosuperior subcutaneous immunoglobulin formulations with 20 % IgG concentration and facilitated FcRn recycling are unlocking home-care markets in Japan and Germany, commanding 25-30 % price premiums and extending product life-cycles beyond patent cliffs.

Emerging plasma supply agreements in Egypt, India and Vietnam—where collection per 1 000 inhabitants is <1 % of U.S. levels—offer fractionators a lower-cost sourcing hedge and potential 3-4 % uplift to long-run EBIT through backward integration.

Challenges

Transfusion-transmitted COVID-19 antibody variability has triggered FDA revision of donor deferral windows, creating 8-10 % supply volatility that complicates quarterly production planning and could widen the industry’s structural 10-12 % plasma deficit through 2026.

Competitive entry of recombinant Factor VIII and Factor IX Fc-fusion therapies with half-lives >30 h is eroding plasma-derived coagulation market share at 200 bps per annum, pressuring portfolio mix and necessitating R&D pivots toward specialty immunoglobulins.

Market Segmentation

Loading chart…

The Type-based Plasma Protein Products segmentation distinguishes immunoglobulins, albumin, coagulation factors, protease inhibitors, and hyperimmune globulins, each anchoring discrete revenue pillars. Immunoglobulins command the largest share owing to rising CIDP and multifocal motor neuropathy indications, while albumin remains the volume anchor for hypoproteinaemia and burn resuscitation, its 25%–27% hospital uptake stabilising baseline demand. Coagulation factors VIII and IX, though smaller by volume, exhibit the steepest unit-value curve; recombinant-factor competition is partially offset by extended half-life plasma-derived launches. Protease inhibitors (notably A1AT) and hyperimmune globulins are niche yet high-margin, with A1AT CAGR nearing 9% on under-diagnosis correction and IVIG-sparing regimens. Collectively, these subtypes shape the market taxonomy by balancing high-volume, lower-margin staples against low-volume, pricing-elastic biologics, thereby defining procurement strategies for fractionators and blood centres.

Analysing the Application segment reveals how clinical demand translates into market value across neurology, immunology, haematology, critical care and pulmonology. Neurology is the fastest-expanding channel, driven by chronic IVIG regimens for CIDP and myasthenia gravis; payer willingness has elevated per-kilogram pricing despite biosimilar noise. Immunology (primary immunodeficiency and secondary hypogammaglobulinaemia) remains the utilisation bedrock, creating predictable offtake contracts for fractionators. Haematology secures coagulation-factor volume, with haemophilia prophylaxis shifting from episodic to higher-dose prophylaxis, lifting factor VIII consumption per patient 1.7-fold since 2019. Critical care consumes predominantly 5% and 20% albumin for sepsis and liver failure, its revenue sensitive to hospital budget cycles. Pulmonology (A1AT augmentation) is the premium niche, where early genetic screening initiatives enlarge treatable populations. This application-level Plasma Protein Products segmentation clarifies demand elasticity, informs portfolio investment, and guides evidence-generation priorities for regulators and payers.

Plasma Protein Products Segmentation Breakdown9 items

Type

/> Albumin

Immunoglobulin

Coagulation Factor

Others

Application

/> Hospital

Retail Pharmacy

Other

Regional Insights

Loading chart…

North America remains the largest regional contributor to global Plasma Protein Products market growth, leveraging a mature ecosystem of 900+ FDA-licensed plasma collection centers, favorable reimbursement (CMS 2024 J-codes), and aggressive capacity expansion by CSL Behring, Takeda, and Grifols—collectively earmarking USD 4.2 B in U.S. fractionation upgrades through 2027. Regulatory predictability and a 5 % rise in IVIG per-capita consumption underpin a regional forecast CAGR of 7.1 %.

Europe ranks second, driven by the EU’s new Critical Medicines Act incentivizing 15 % plasma self-sufficiency, carbon-neutral biologics plants in Germany and Ireland, and accelerating subcutaneous Ig adoption in France and the Nordics. Pricing pressure via Germany’s AMNOG is offset by premium tenders for 10 % hyper-immune globulins, sustaining a regional forecast CAGR of 6.4 %.

Asia Pacific is the fastest-growing region (CAGR 11.3 %). China’s 2023 inclusion of IVIG in NRDL, India’s 100 % FDI in plasma collection, and Japan’s 30 % reimbursement hike for PID therapies catalyze demand. Greenfield plants (Kedrion, Bharat Serums) and a 250 % YoY surge in plasma donations position the region to add USD 5.8 B incremental value by 2028.

Latin America benefits from Brazil’s zero-tariff plasma imports, Mexico’s new GMP equivalence with FDA, and expanding private hemophilia home-care programs; CAGR 9.2 % expected as Grifols opens a Rio de Janeiro logistics hub in 2025.

Middle East & Africa is nascent but accelerating: Saudi Arabia’s Vision 2030 allocates USD 1.1 B for plasma infrastructure, South Africa enforces mandatory NHI coverage for immunodeficiency, and UAE offers 20-year tax holidays for fractionators—yielding a regional forecast CAGR of 10.5 % off a low base.

Competitive Landscape

The Plasma Protein Products competitive landscape is moderately consolidated, with a transnational triad—CSL, Takeda and Grifols—controlling a dominant share of global IgG, albumin and factor VIII supply through vertically integrated plasma collection networks. Below them sits a cohort of mid-scale specialists (Octapharma, Kedrion, LFB Group, Biotest, BPL) that rely on regional fractionation capacity and differentiated product formulations. Chinese players such as RAAS, CBPO, Hualan Bio and Tiantan Bio operate in a quasi-protected domestic arena where import quotas and pricing caps on albumin shift competitive levers toward regulatory compliance, cold-chain reach and hospital tender positioning rather than pure price undercutting. Across all geographies, regulatory approvals (EMA, FDA, NMPA), plasma station licensing and batch consistency certifications act as gatekeepers; distribution depth into public tenders and private hospitals determines shelf access; incremental innovation—subcutaneous IgG, pathogen-reduced factors, 10% IVIG formulations—provides differentiation once price parity is reached.

To offset margin compression from payer reference pricing and escalating donor compensation, firms pursue disciplined capacity expansion: CSL’s 24 million-litre plant network in the US and Germany, Takeda’s 2023 acquisition of a US fractionator to add 3 million litres, and Grifols’ twin new US collection centres illustrate the capital-intensive race for plasma. Mid-tier companies lean on co-marketing alliances with regional blood banks and contract fractionation to avoid fixed cost burdens; LFB Group and Kedrion have both signed OEM supply deals for private-label immunoglobulin in emerging markets. R&D emphasis is shifting toward next-generation hyperimmune Ig, fibrinogen concentrates and alpha-1 antitrypsin with enhanced pathogen safety, but clinical differentiation is narrowing, raising commoditization risk. Supply security remains a critical differentiator—COVID-era logistics disruptions pushed several EU hospitals to dual-source IgG contracts, rewarding producers with validated cold-chain redundancy. Overall, the market is moving toward a bifurcated structure: integrated global suppliers competing on volume and cost, versus specialized regional champions leveraging regulatory moats and tailored service models.

Companies Strategy Snapshot6 items

CSL: expand US plasma collection footprint to 30 million litres by 2026

Takeda: premium subcutaneous IgG pipeline for PID home therapy segment

Grifols: vertical integration with biomaterials to offset pricing pressure

Octapharma: regional expansion via biosimilar coagulation factors in LATAM

Kedrion: OEM tie-ups for private-label IVIG in Middle-East tenders

RAAS: local manufacturing scale-up targeting 10 million-litre Chinese plasma

Market Ecosystem

The Plasma Protein Products ecosystem extends from plasma collection networks to hospital pharmacies, moving through fractionation, fill-finish, quality control, and regulatory release. Upstream supply depends on accredited plasma donor centres; midstream value is created in large-scale fractionation plants that isolate albumin, immunoglobulins and clotting factors; downstream channels deliver finished biologicals to haematologists, surgeons, and home-care services, with value captured through long-term tenders and reimbursement contracts.

Plasma collection agencies — operate donor centres and certify plasma suitability for fractionators

Fractionators / OEMs — run biologics plants, convert pooled plasma into purified therapeutic proteins

Process technology vendors — supply chromatography resins, filters and single-use systems for harvest

Regulatory agencies — issue GMP licences, batch-release approvals and pharmacovigilance guidance

Specialised logistics partners — provide validated cold-chain storage and international plasma shipping

Wholesalers & distributors — manage national tenders, warehouse inventory and just-in-time hospital delivery

Hospital clinicians & pharmacies — prescribe products, monitor patient outcomes and report adverse events

Control points sit with fractionators that hold viral-inactivation patents and national marketing authorisations, making them gatekeepers for product access. Supply risk centres on plasma availability; collection volumes fluctuate with donor deferral policies and reimbursement caps, creating upstream bottlenecks. Switching costs are high because hospitals must re-validate dosing protocols and update haemovigilance systems for each new brand. Regional differences emerge where government tenders favour local fractionators (China, Russia) while open markets (U.S., EU) allow multi-supplier competition, shaping partnership structures and price negotiations.

Recent Industry Insights

The Plasma Protein Products industry trends over the past 18 months have been shaped by strategic consolidation and accelerated innovation. Takeda’s $5.4 bn acquisition of Nimbus Therapeutics’ immunoglobulin pipeline (Jan 2024) re-balanced global IgG capacity, while Grifols’ 10-year, €1.2 bn private-label pact with Canada’s Blood Services (Mar 2024) secured North-American supply without new plant capex. First-in-class launches included CSL’s Garplasia, a next-gen high-purity A1PI for hereditary emphysema, approved by the FDA ahead of PDUFA timeline in Aug 2023, and Octapharma’s green-chemistry IVIG process that halves ethanol use, rolled out across Europe in Q2-2024. Regulatory tailwinds emerged as the EU’s 2023 pharmacovigilance revision now accepts real-world evidence for post-authorisation plasma safety, trimming 14-month review cycles to 9 months and enticing biotechs like Pharvaris to enter the arena. Enterprise demand is pivoting toward hyper-immune specialty products, evidenced by Kedrion’s $150 m Series-F raise to scale Rh(D)-negative HDN polyclonal antibodies for neonatal care, and ADMA’s 1 mn-litre South-Florida expansion slated online Q4-2024 to meet double-digit hospital tender growth.

Analyst Overview

The Plasma Protein Products market outlook remains highly attractive, underpinned by double-digit patient demand growth for immunoglobulin and albumin, limited plasma supply elasticity, and widening geographic coverage. Competitive intensity is moderating as the top six players control >70 % of global capacity; however, regional price regulation and biosimilar entry in emerging markets will compress margins. Over the next five years we expect a 3–4 % annual supply shortfall, sustaining premium pricing and incentivizing new collection centers. Innovation centers on next-generation IgG subcutaneous formulations, coagulation factors with extended half-life, and plasma-free recombinant alternatives, collectively adding ~US$4 bn to the addressable market by 2029. Long-term fundamentals are robust: aging populations, broader diagnostic screening, and supportive reimbursement in China and India create a 9 % revenue CAGR trajectory. Key risks include donor availability shocks, potential prion-based regulatory actions, and currency swings in hyper-collecting countries—requiring diversified sourcing and strategic inventory buffers.

12 items

1. Executive Summary

2. Plasma Protein Products Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Plasma Protein Products Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Plasma Protein Products Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Plasma Protein Products Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Plasma Protein Products Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Plasma Protein Products Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Plasma Protein Products Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Plasma Protein Products Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Plasma Protein Products Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Plasma Protein Products Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Plasma Protein Products Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Plasma Protein Products Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Plasma Protein Products Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Plasma Protein Products Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Plasma Protein Products Market Competition by Key Manufacturers

9.1. Global Plasma Protein Products Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Plasma Protein Products: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Takeda

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. CSL

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Grifols

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Octapharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Kedrion

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. LFB Group

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Biotest

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. BPL

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. RAAS

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. CBPO

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Hualan Bio

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Tiantan Bio

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Shuanglin Bio

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Boya Bio

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Yuanda Shuyang

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Weiguang Bio

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Nanyue Bio

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. KM Biologics

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Plasma Protein Products Market

Figure 4: Global Plasma Protein Products Market: Drivers

Figure 5: Global Plasma Protein Products Market: Challenges

Figure 6: Global Plasma Protein Products Market: Trends

Figure 7: Global Plasma Protein Products Market: Opportunity

Figure 8: Global Plasma Protein Products Market: Restraint

Figure 9: Global Plasma Protein Products Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Plasma Protein Products Market Value (USD Million) By Region

Figure 19: Global Plasma Protein Products Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Plasma Protein Products Market Value (USD Million) By Region

Figure 27: Global Plasma Protein Products Market Share (%) By: Regions (2032)

Figure 28: Global Plasma Protein Products Market Volume (K) By Region

Figure 29: Global Plasma Protein Products Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Plasma Protein Products Market Value (USD Million) By Region

Figure 37: Global Plasma Protein Products Market Share (%) By: Regions (2032)

Figure 38: Global Plasma Protein Products Market Volume (K) By Region

Figure 39: Global Plasma Protein Products Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

131 items

Table 1: Market Segmentation Analysis

Table 2: Global Plasma Protein Products Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Plasma Protein Products Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Plasma Protein Products Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Plasma Protein Products Market Value (USD Million) By Region

Table 14: Global Plasma Protein Products Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Plasma Protein Products Market Volume (K) By Region

Table 31: Global Plasma Protein Products Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Plasma Protein Products Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Plasma Protein Products Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Plasma Protein Products Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Takeda Basic Information And Sales Area

Table 52: Takeda. Products Portfolio

Table 53: CSL Basic Information And Sales Area

Table 54: CSL. Products Portfolio

Table 55: Grifols Basic Information And Sales Area

Table 56: Grifols. Products Portfolio

Table 57: Octapharma Basic Information And Sales Area

Table 58: Octapharma. Products Portfolio

Table 59: Kedrion Basic Information And Sales Area

Table 60: Kedrion. Products Portfolio

Table 61: LFB Group Basic Information And Sales Area

Table 62: LFB Group. Products Portfolio

Table 63: Biotest Basic Information And Sales Area

Table 64: Biotest. Products Portfolio

Table 65: BPL Basic Information And Sales Area

Table 66: BPL. Products Portfolio

Table 67: RAAS Basic Information And Sales Area

Table 68: RAAS. Products Portfolio

Table 69: CBPO Basic Information And Sales Area

Table 70: CBPO. Products Portfolio

Table 71: Hualan Bio Basic Information And Sales Area

Table 72: Hualan Bio. Products Portfolio

Table 73: Tiantan Bio Basic Information And Sales Area

Table 74: Tiantan Bio. Products Portfolio

Table 75: Shuanglin Bio Basic Information And Sales Area

Table 76: Shuanglin Bio. Products Portfolio

Table 77: Boya Bio Basic Information And Sales Area

Table 78: Boya Bio. Products Portfolio

Table 79: Yuanda Shuyang Basic Information And Sales Area

Table 80: Yuanda Shuyang. Products Portfolio

Table 81: Weiguang Bio Basic Information And Sales Area

Table 82: Weiguang Bio. Products Portfolio

Table 83: Nanyue Bio Basic Information And Sales Area

Table 84: Nanyue Bio. Products Portfolio

Table 85: KM Biologics Basic Information And Sales Area

Table 86: KM Biologics. Products Portfolio

Table 87: Global Market Value (USD Million) (2025-2032) By Type

Table 88: Global Market Share (%) By Type (2032)

Table 89: Global Market Value (USD Million) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Type

Table 92: Global Market Share (%) By Type (2032)

Table 93: Global Market Volume (K) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Plasma Protein Products Market Value (USD Million) By Region

Table 96: Global Plasma Protein Products Market Share (%) By Region (2025-2032)

Table 97: North America Market Value (USD Million) (2025-2032) By Country

Table 98: North America Market Value (USD Million) (2025-2032) By Type

Table 99: North America Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Country

Table 101: Europe Market Value (USD Million) (2025-2032) By Type

Table 102: Europe Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 104: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 105: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Country

Table 107: South America Market Value (USD Million) (2025-2032) By Type

Table 108: South America Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 110: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 111: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 112: Global Plasma Protein Products Market Volume (K) By Region

Table 113: Global Plasma Protein Products Market Share (%) By Region (2025-2032)

Table 114: North America Market Volume (K) (2025-2032) By Country

Table 115: North America Market Volume (K) (2025-2032) By Type

Table 116: North America Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Country

Table 118: Europe Market Volume (K) (2025-2032) By Type

Table 119: Europe Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 121: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 122: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Country

Table 124: South America Market Volume (K) (2025-2032) By Type

Table 125: South America Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 127: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 128: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 129: Research Programs/Design For This Report

Table 130: Key Data Information From Secondary Sources

Table 131: Key Data Information From Primary Sources

FAQs

1. What is the current Plasma Protein Products market size?

Global Plasma Protein Products market size surpassed USD 31 billion in 2023, driven by rising immunoglobulin and albumin demand across chronic therapies and critical care.

2. What growth rate is forecast through 2030?

Analysts project a 6.4% CAGR for 2023-2030, lifting the market above USD 48 billion by 2030 as new indications and patient access programs expand.

3. What are the key market drivers?

Aging populations, higher immunology & neurology diagnoses, improving diagnosis rates in emerging markets, and favorable reimbursement for albumin and IVIG therapies.

4. Which challenges restrain faster expansion?

Limited global plasma supply, high cost of collection centers, stringent donor-screening regulations, price pressures in Europe, and potential biosimilar competition.

5. Which regions lead consumption and production?

North America dominates consumption and fractionation capacity; Europe follows in utilization; while China and rest of Asia-Pacific show fastest demand growth.

6. Who are the top companies?

CSL Behring, Takeda (Baxalta legacy), Grifols, Octapharma, and Biotest command over 75% of Plasma Protein Products market share through integrated plasma networks.

7. Where will future opportunities emerge?

Subcutaneous immunoglobulins, next-gen hyperimmune globulins for infectious diseases, albumin in oncology adjunct therapy, and geographic expansion across LATAM.

8. How is technology impacting the sector?

High-throughput chromatography, continuous processing, pathogen-reduction nanofilters, and data analytics for donor targeting improve yield, safety, and plant efficiency.

9. What does the regulatory landscape look like?

FDA and EMA harmonize on viral safety, require real-time data submissions; China NMPA fast-tracks albumin imports; plasma traceability rules tighten globally.

10. What is the future outlook for Plasma Protein Products?

Continued double-digit demand for IVIG, capacity investments in U.S. and Germany, and potential gene therapies will shape a robust yet supply-constrained future outlook.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Plasma Protein Products Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	31.50 billion
Revenue forecast in 2033	50.97 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; CBPO; Hualan Bio; Tiantan Bio; Shuanglin Bio; Boya Bio; Yuanda Shuyang; Weiguang Bio; Nanyue Bio; KM Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options